CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer

Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management